英文名稱 | Ruxolitinib sulfate | INCB018424 sulfate |
---|---|
中文名稱 | 魯索替尼硫酸鹽 | 魯索利替尼硫酸鹽 |
CAS號 | 1092939-16-6 |
分子式 | C17H18N6 · H2SO4 |
分子量 | 404.44 | 306.37(free) |
外觀 | Off-white to gray powder |
儲存條件 | 4°C, sealed storage, away from moisture |
英文名稱 | Ruxolitinib sulfate | INCB018424 sulfate |
---|---|
中文名稱 | 魯索替尼硫酸鹽 | 魯索利替尼硫酸鹽 |
CAS號 | 1092939-16-6 |
分子式 | C17H18N6 · H2SO4 |
分子量 | 404.44 | 306.37(free) |
外觀 | Off-white to gray powder |
儲存條件 | 4°C, sealed storage, away from moisture |
Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.
PMID: 20130243 PMCID: PMC3953826 DOI: 10.1182/blood-2009-04-214957
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
PMID: 22375970 DOI: 10.1056/NEJMoa1110556
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
PMID: 22375970 DOI: 10.1056/NEJMoa1110556